SEP 4, 2026 · PHASE 2 TRIAL
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
ClinicalTrials.gov
This is a Phase 2 interventional trial still recruiting with no results posted; it represents early-stage hypothesis testing in a defined patient population.
Reported
Planned enrollment174
PhasePhase 2
Primary outcome measureProgression-Free Survival (PFS)